Phase 3
N=800
WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients With Atrial Fibrillation
Atrial Fibrillation · Stroke
Bottom Line
View on ClinicalTrials.gov: NCT00129545 ↗Enrolled (actual)
800
Serious AEs
30.3%
Results posted
May 2015
Primary outcome: Primary: Composite of Stroke, Systemic Embolism and Cardiovascular or Unexplained Death — 2.2; 3.7 events per 100 pt yrs
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- WATCHMAN Left Atrial Appendage Closure Technology (Device); Warfarin (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Boston Scientific Corporation
- Primary completion
- Aug 2013
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Composite of Stroke, Systemic Embolism and Cardiovascular or Unexplained Death |
2.2; 3.7 | — |
| PRIMARY The Occurrence of Life-threatening Events, Including Device Embolization or Serious Bleeding Events |
3.5; 3.2 | — |
| SECONDARY Procedure Success |
90.9 | — |
Summary
This is a multi-center, prospective, randomized study, stratified by center, comparing the WATCHMAN device to long term warfarin therapy, demonstrating that the treatment arm is non-inferior to the control arm. This study was amended to allow for a non-randomized arm and increased enrollment.
Eligibility Criteria
Inclusion Criteria
- Patient has paroxysmal, persistent or permanent non-valvular atrial fibrillation (AF)
- Eligible for long term warfarin
- CHADS score >= 1 [congestive heart failure (CHF), history of high blood pressure, 75 years of age or older, diabetes, prior stroke or transient ischemic attack (TIA)]
Exclusion Criteria
- Contraindicated for warfarin
- Contraindicated for aspirin or clopidogrel (Plavix)
- Congestive heart failure (CHF) Class 4
- Implanted mechanical valve
- Atrial septal or Patent Foramen Ovale (PFO) device
- Platelets < 100, 000 or hemoglobin < 10
- Left ventricular ejection fraction (LVEF) < 30%
Data sourced from ClinicalTrials.gov (NCT00129545). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.